Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Other Non-Current Assets (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Other Non-Current Assets readings, the most recent being $70000.0 for Q3 2017.

  • On a quarterly basis, Other Non-Current Assets fell 74.07% to $70000.0 in Q3 2017 year-over-year; TTM through Sep 2017 was $70000.0, a 74.07% decrease, with the full-year FY2016 number at $15000.0, down 66.67% from a year prior.
  • Other Non-Current Assets hit $70000.0 in Q3 2017 for Eledon Pharmaceuticals, up from $15000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $270000.0 in Q1 2016 to a low of $15000.0 in Q4 2016.
  • Median Other Non-Current Assets over the past 5 years was $95000.0 (2017), compared with a mean of $129642.9.
  • Biggest five-year swings in Other Non-Current Assets: surged 500.0% in 2016 and later tumbled 94.44% in 2017.
  • Eledon Pharmaceuticals' Other Non-Current Assets stood at $50000.0 in 2013, then soared by 300.0% to $200000.0 in 2014, then crashed by 77.5% to $45000.0 in 2015, then crashed by 66.67% to $15000.0 in 2016, then soared by 366.67% to $70000.0 in 2017.
  • The last three reported values for Other Non-Current Assets were $70000.0 (Q3 2017), $15000.0 (Q2 2017), and $120000.0 (Q1 2017) per Business Quant data.